Trial site
Wielospecjalistyczne Centrum Medyczne "Ibismed" s.c.
Zabrze, 41-800, PolandEU-13 widening countryNot linked to an institution yet
- 9running trials
- 1closed trial
The trials here
What the 10 trials at this site are about, from their registry records.
- Phase
- Phase 36 trials
- Phase 23 trials
- Phase 11 trial
- Status
- Active, not recruiting5 trials
- Not yet recruiting3 trials
- Completed1 trial
- Recruiting1 trial
- Lead sponsor
- Sanofi2 trials
- Immunic AG1 trial
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany1 trial
- Novartis Pharmaceuticals1 trial
- Polpharma Biologics International AG1 trial
- and 4 more
Running trials
Recruiting
A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
NCT07673744· Phase 2· TG Therapeutics, Inc.· Source
Not yet recruiting
A Biosimilar Trial to Investigate PK, PD, Safety With PB018 Versus US-licensed Ocrevus and EU-approved Ocrevus
NCT07606521· Phase 1· Polpharma Biologics International AG· Source
Recruiting
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
NCT07325292· Phase 3· Sanofi· Source
Recruiting
A Phase 2 Study of Obexelimab in Patients with Relapsing Multiple Sclerosis
2024-512707-40-00· Phase 2· Zenas Biopharma (USA) LLC· Source
Recruiting
Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis
2023-504358-36-00· Phase 3· Sanofi-Aventis Recherche & Developpement· Source
Recruiting
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
NCT06463587· Phase 3· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Source
Active, not recruiting
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486· Phase 3· Sanofi· Source
Active, not recruiting
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
NCT05201638· Phase 3· Immunic AG· Source
Active, not recruiting
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05156281· Phase 3· Novartis Pharmaceuticals· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error